Alosetron
CAS No. 122852-42-0
Alosetron ( GR-68755X;GR-68755 )
Catalog No. M10888 CAS No. 122852-42-0
A potent and selective 5-HT3 receptor antagonist has been shown to be beneficial in the treatment of irritable bowel syndrome.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
200MG | 1078 | Get Quote |
|
500MG | Get Quote | Get Quote |
|
1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameAlosetron
-
NoteResearch use only, not for human use.
-
Brief DescriptionA potent and selective 5-HT3 receptor antagonist has been shown to be beneficial in the treatment of irritable bowel syndrome.
-
DescriptionA potent and selective 5-HT3 receptor antagonist has been shown to be beneficial in the treatment of irritable bowel syndrome.Irritable Bowel Syndrome Approved
-
SynonymsGR-68755X;GR-68755
-
PathwayEndocrinology/Hormones
-
Target5-HT Receptor
-
Recptor5-HT Receptor
-
Research AreaOther Indications
-
IndicationIrritable Bowel Syndrome
Chemical Information
-
CAS Number122852-42-0
-
Formula Weight294.35
-
Molecular FormulaC17H18N4O
-
Purity>98% (HPLC)
-
Solubility10 mM in DMSO
-
SMILESCc1c([nH]cn1)CN2CCc3c(c4ccccc4n3C)C2=O
-
Chemical Name1H-Pyrido[4,3-b]indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2-[(4-methyl-1H-imidazol-5-yl)methyl]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Audolfsson G, et al. Aliment Pharmacol Ther. 1999 May;13 Suppl 2:39-47.
2. Zhai J, et al. J Pharmacol Exp Ther. 1999 Oct;291(1):374-82.
3. Saslow SB, et al. Gut. 1998 May;42(5):628-34.
2. Zhai J, et al. J Pharmacol Exp Ther. 1999 Oct;291(1):374-82.
3. Saslow SB, et al. Gut. 1998 May;42(5):628-34.
molnova catalog
related products
-
Ramosetron hydrochlo...
Ramosetron hydrochloride is a serotonin 5-HT3 receptor antagonist.
-
Nelotanserin
A potent, selective 5-HT2A inverse agonist with pKi of 9.2; displays >30- and 5000-fold selectivity compared with 5-HT2C and 5-HT2B receptors.
-
JNJ-5234801
JNJ-5234801 is an atypical anxiolytic targeting 5-HT2 receptor, has demonstrated oral activity in animal models of anxiety.